ABUS Arbutus Biopharma Corporation

4.38
-0.01  -0%
Previous Close 4.39
Open 4.35
Price To Book 2.65
Market Cap 242990289
Shares 55,477,235
Volume 214,666
Short Ratio
Av. Daily Volume 433,808

SEC filingsSee all SEC filings

  1. 8-K - Current report 181201530
  2. 8-K - Current report 181167314
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167308
  4. 8-K - Current report 181131584
  5. 8-K - Current report 181112307

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but no plans to continue further development.
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
ARB-1467
Hepatitis B (HBV)
Phase 1 trial initiation delayed - noted October 9, 2018.
AB-452
Hepatitis B
Phase 1 trial to be completed 2Q 2019.
AB-506
Hepatitis B (HBV)

Latest News

  1. New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset Management, FormFactor, and Arbutus Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018
  2. Is PennyMac Financial Services Inc (PFSI) A Good Stock To Buy?
  3. Why Arbutus Biopharma Corporation’s (NASDAQ:ABUS) CEO Pay Matters To You
  4. Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
  5. Options Traders Expect Huge Moves in Arbutus (ABUS) Stock
  6. Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
  7. Arbutus to Report Third Quarter 2018 Financial Results
  8. Arbutus Names New Members to its Board of Directors
  9. New Research Coverage Highlights Arbutus Biopharma, Tata Motors, Core-Mark Holding, Tenaris S.A, Addus HomeCare, and ZTO Express (Cayman) — Consolidated Revenues, Company Growth, and Expectations for 2018
  10. What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)?
  11. Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
  12. Today's Research Reports on Trending Tickers: Arbutus Biopharma and Akcea Therapeutics
  13. Why Arbutus Biopharma Stock Plunged 24.4% Today
  14. Here's Why Arbutus Biopharma Corp. Is Tanking Today
  15. Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
  16. Arbutus to Present at Chardan’s Genetic Medicines Conference
  17. Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?
  18. Why Dicerna Pharmaceuticals Stock Rose 7.7% Yesterday
  19. Why Arrowhead Pharmaceuticals Stock Is Skyrocketing Today

SEC Filings

  1. 8-K - Current report 181201530
  2. 8-K - Current report 181167314
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167308
  4. 8-K - Current report 181131584
  5. 8-K - Current report 181112307
  6. 8-K - Current report 181040270
  7. 8-K - Current report 181010352
  8. 8-K - Current report 181006651
  9. 8-K - Current report 18990144
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18989791